Menu Search
Equities

Paradigm Biopharmaceuticals Ltd

P86:DEU

Paradigm Biopharmaceuticals Ltd

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Paradigm Biopharmaceuticals Ltd's revenues fell -23.22% from 8.49m to 6.52m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 51.91m to a larger loss of 58.65m.
Gross margin99.86%
Net profit margin-899.60%
Operating margin-898.66%
Return on assets-124.19%
Return on equity-151.39%
Return on investment-150.28%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Paradigm Biopharmaceuticals Ltd fell by 38.51m. Cash Flow from Financing totalled 28.18m or 432.17% of revenues. In addition the company used 65.94m for operations while cash used for investing totalled .
Cash flow per share-0.167
Price/Cash flow per share--
Book value per share0.068
Tangible book value per share0.0595
More ▼

Balance sheet in AUDView more

Paradigm Biopharmaceuticals Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio7.22
Quick ratio--
Total debt/total equity0.006
Total debt/total capital0.006
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.